(Press-News.org) (ORLANDO, Dec. 6, 2025) Patients who underwent hematopoietic cell transplantation for sickle cell disease saw high rates of survival without disease symptoms and low rates of severe side effects or complications years after their procedure, according to a new study. The study included over 1,000 patients, representing the largest and most comprehensive analysis of long-term transplant outcomes to date in people living with sickle cell disease.
“A majority of patients in this cohort are alive; the transplant worked so they no longer show symptoms of their sickle cell disease, and most have had no late effects post-transplant,” said lead study author Elizabeth Stenger, MD, associate professor in the department of pediatrics at Emory University School of Medicine and pediatric hematologist/oncologist at the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta in Georgia. “There are families that really want to know the data, and this will be among the largest and most statistically well-powered studies that can provide this information to patients we are counseling about transplant.”
Hematopoietic cell transplantation can eliminate symptoms of sickle cell disease by giving patients the ability to make healthy blood cells instead of ones prone to sickling. For the procedure, patients first undergo a chemotherapy-based conditioning regimen to clear the bone marrow of their own stem cells. Stem cells from a healthy donor are then infused and migrate to the bone marrow, where they begin producing healthy blood cells.
This procedure has been in use for several decades, but strategies for donor matching and conditioning have evolved over time. Long-term outcomes from hematopoietic cell transplantation, as it is currently practiced, have not been well studied in people living with sickle cell disease. In particular, it is unknown whether patients may face unique long-term effects of chemotherapy conditioning due to sickle cell disease-related organ damage.
Researchers analyzed data from 1,013 patients who received a hematopoietic cell transplant at 112 medical centers in the United States and internationally between 1996 to 2022. About half were female and just over half had a matched related donor. Procedures that resulted in primary graft failure (meaning that the donor stem cells did not persist early after transplant) were excluded from the data set.
At seven years post-transplant, 90% of transplant recipients remained alive, 83% were alive and had experienced no issues with transplant rejection, and 63% were alive without having experienced any late rejection or severe graft-versus-host disease (GVHD), a condition in which the transplanted donor cells attack the recipient’s body.
Sickle cell disease outcomes, which were assessed at a median of five years post-transplant, were also largely positive. Most patients (86%) remained free from sickle cell disease symptoms with hemoglobin S levels at or below 50%, and most (74%) had no sickle cell disease-related complications reported at any time point post-transplant.
Excluding infections, the most common late effects of transplant were those affecting the liver (seen in 10% of patients at seven years post-transplant), lungs (8%), reproductive organs (6%), and pancreas (i.e., diabetes; 6%). Of the 9% of patients who died, the most common causes of death were organ failure, infection, and GVHD.
Factors associated with better outcomes included being younger at the time of transplant, having a matched related donor instead of a genetically mismatched or unrelated donor, and having bone marrow instead of peripheral blood as the source of donated cells.
Remaining free of GVHD was also significantly associated with better long-term outcomes. At a median of five years, 26% of patients had experienced chronic GVHD and 30% had experienced acute GVHD, both of any severity.
Given its uniquely large sample with heterogenous transplant characteristics, researchers said that the study findings can help families and doctors make informed decisions about whether – and when – to pursue a transplant. “This study can provide more concrete data about [the risks and benefits] if transplant is undertaken early versus waiting,” said Dr. Stenger. “Right now, allogeneic hematopoietic cell transplantation is the only known and available option for this population capable of eliminating the full spectrum of disease symptoms. Especially if we do it while patients are young or before the onset of organ damage, these patients can go on to live much more normal lives.”
The study also underscores the importance of ongoing health monitoring following a transplant. “From a clinical standpoint, [it reinforces] the need to make sure these patients are having the recommended annual follow-up to screen and monitor for late effects so that if they are happening, we can catch them early and hopefully prevent them from becoming symptomatic and more clinically significant,” said Dr. Stenger.
Since the study relied on data provided to a registry, researchers noted that the level of detail is somewhat limited for some factors.
Researchers are now working to compare survival outcomes among people living with sickle cell disease who received a hematopoietic cell transplant versus those who did not receive a transplant including those who received disease-modifying treatment. Dr. Stenger said that additional insights on potential late effects could be gained through future studies with a longer follow-up period.
Elizabeth Stenger, MD, of Emory University School of Medicine and the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta, will present this study on Monday, December 8, 2025, at 4:30 p.m. Eastern time in W331 of the Orange County Convention Center.
###
The American Society of Hematology (ASH) (hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. Since 1958, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. Join the #Fight4Hematology by visiting hematology.org/fight4hematology.
The Blood journals (https://ashpublications.org/journals) are the premier source for basic, translational, and clinical hematologic research. The Blood journals publish more peer-reviewed hematology research than any other academic journals worldwide.
The ASH Center for Sickle Cell Disease Initiatives (hematology.org/ash-center-for-sickle-cell-disease-initiatives) is committed to progressing research in sickle cell disease by targeting critical needs and generating powerful, real-world evidence to create impact and change.
END
Long-term outlook is positive for most after hematopoietic cell transplant for sickle cell disease
2025-12-06
ELSE PRESS RELEASES FROM THIS DATE:
Study offers real-world data on commercial implementation of gene therapies for sickle cell disease and beta thalassemia
2025-12-06
(ORLANDO, Dec. 6, 2025) The first study assessing the real-world commercial roll-out of gene therapies for sickle cell disease and beta thalassemia offers lessons learned to inform best practices as manufacturers and medical centers prepare to meet growing demand for gene therapies in the coming years.
“Gene therapy requires system-level coordination and close collaboration across patients, treatment centers, payers, and manufacturers,” said study author Joanne Lager, MD, chief medical officer at Genetix Biotherapeutics Inc. “The demand for these one-time durable gene ...
Early results suggest exa-cel gene therapy works well in children
2025-12-06
(ORLANDO, Dec. 6, 2025) Preliminary results from two trials of the gene therapy exagamglogene autotemcel (exa-cel) suggest the therapy offers an effective cure for beta-thalassemia and sickle cell disease in children younger than 12. Researchers say the therapy’s potential to offer a cure at an early age – before organ damage accumulates – could make exa-cel even more beneficial in children than adults.
“All younger patients with sufficient follow-up met the primary endpoint of being transfusion independent in those with beta thalassemia and free of vaso-occlusive crises for those with sickle cell disease,” said ...
NTIDE: Disability employment holds steady after data hiatus
2025-12-05
East Hanover, NJ – December 5, 2025 – The December 2025 National Trends in Disability Employment (nTIDE) report shows that employment outcomes for working-aged people with disabilities remain near historic highs, despite broader economic uncertainty. nTIDE reporting was on hiatus while the federal government shutdown delayed the release of employment data, which only recently became available.
Although employment and labor force participation edged down slightly in September, both measures continue to outperform year-to-year trends for workers without disabilities. Overall, the findings point to sustained labor market engagement among people with disabilities, ...
Social lives of viruses affect antiviral resistance
2025-12-05
Interactions among viruses can help them succeed inside their hosts or impart vulnerabilities that make them easier to treat. Scientists are learning the ways viruses mingle inside the cells they infect, as well as the consequences of their socializing.
Ph.D. student Alexander J. Robertson in the Molecular & Cellular Biology program at the University of Washington is among those scientists.
“I study the evolution of antimicrobial resistance through mechanisms which require interaction between microbes,” he explained.
This week he is the lead author of a paper in Nature Ecology & Evolution on that topic.
Polioviruses ...
Dose of psilocybin, dash of rabies point to treatment for depression
2025-12-05
ITHACA, N.Y. – An international collaboration led by Cornell University researchers used a combination of psilocybin and the rabies virus to map how – and where – the psychedelic compound rewires the connections in the brain.
Specifically, they showed psilocybin weakens the cortico-cortical feedback loops that can lock people into negative thinking. Psilocybin also strengthens pathways to subcortical regions that turn sensory perceptions into action, essentially enhancing sensory-motor responses.
The ...
Helping health care providers navigate social, political, and legal barriers to patient care
2025-12-05
In November, The Lancet, one of the world’s most esteemed medical journals, launched a new monthly series of case studies that goes beyond clinical diagnoses to illuminate the social and cultural forces that contribute to each patient’s condition.
Clinical case studies have long been a fixture in medical journals and are a primary way doctors and other health professionals continue learning after their initial training. Typically, case studies are short summaries of a patient’s predicament alongside a clinician’s assessment, diagnosis, ...
Barrow Neurological Institute, University of Calgary study urges “major change” to migraine treatment in Emergency Departments
2025-12-05
Barrow Neurological Institute, University of Calgary study urges “major change” to migraine treatment in Emergency Departments
Advises that injectable treatments must be offered, reducing reliance on opioids
PHOENIX – A new study by Phoenix’s Barrow Neurological Institute and the University of Calgary has found which injectable treatments showed the most benefit for migraine patients and should be routinely offered by Emergency Departments (ED) when feasible. The findings from the study will update the guidelines for the American Headache Society.
Based on a systematic review of clinical trial data, the study ...
Using smartphones to improve disaster search and rescue
2025-12-05
HONOLULU, Dec. 5, 2025 — When a natural disaster strikes, time is of the essence if people are trapped under rubble. Conventional search-and-rescue methods use radar-based detection or employ acoustics that rely on sounds made by victims.
Since most people carry their phones with them every day, Shogo Takada, a student at the University of Tokyo, is working on a way to use smartphone microphones to assist in locating disaster victims.
Takada will present his results Friday, Dec. 5, at 11:45 a.m. HST as part of the Sixth Joint Meeting of the Acoustical Society of America and Acoustical Society of Japan, running Dec. 1-5 in Honolulu, ...
Robust new photocatalyst paves the way for cleaner hydrogen peroxide production and greener chemical manufacturing
2025-12-05
A new study highlights a promising path toward sustainable hydrogen peroxide production using sunlight, oxygen, and water, offering a cleaner alternative to the energy-intensive anthraquinone process that dominates global manufacturing today.
In a commentary published in Sustainable Carbon Materials, researchers Bing Han of North China Electric Power University and Yin Zhang of Nanyang Technological University discuss a recent advancement in covalent organic framework technologies that could reshape photocatalytic chemical synthesis. The featured work, led by Yang and colleagues, demonstrates how a rational redesign of catalyst structures can dramatically boost the efficiency ...
Ultrafast material captures toxic PFAS at record speed and capacity
2025-12-05
Researchers have developed a new material that captures harmful PFAS chemicals from water in a matter of seconds, offering a promising pathway to address one of today’s most persistent environmental threats. The study reports that a nitrate-intercalated layered double hydroxide can remove perfluorooctanoic acid, a widely detected PFAS contaminant, with an exceptional capacity of 1,702 milligrams per gram.
PFAS, often called forever chemicals because of their extreme persistence, are commonly found in drinking water, soils, and even human blood. Traditional adsorbents such as activated carbon and biochar often struggle with limited ...